IVGN: Invitrogen Acquires Fluo 3 and Fluo 4 Product Lines; Products to be Manufactured and Sold Through Invitrogen's Molecular Probes Business

Invitrogen Corporation (Nasdaq:IVGN), a leader in life science research, announced it has completed an asset purchase of fluo 3 and fluo 4 product lines and all related intellectual property from TEF Labs Inc. As a result of the transaction, Invitrogen's Molecular Probes business will assume the manufacture and sale of fluo 3 and fluo 4 from TEF Labs Inc.

"Consolidating fluo 3 and fluo 4 manufacturing under a single roof will ensure consistent ISO 9000 level quality and batch to batch reproducibility -- an essential need for drug discovery scientists," said Augie Sick, Vice President and General Manager of Invitrogen's Cellular Analysis business.

Fluo 3 and fluo 4 are fluorescent indicators which are used to measure the concentration of calcium ions in living cells. These indicators are the work horses of pharmaceutical companies' high throughput screening labs and are widely used in cell-based assays to determine which drug candidates cause or suppress release of intracellular calcium stores. Calcium ion measurements currently comprise more than 1/3 of all ion channel screens and more than 1/2 of all of G protein receptor (GPCR) screens. These ions are critical secondary signaling messengers for a wide range of cellular processes.

"This divestment permits us to focus our resources on the development of new products and technologies," said Dr. Akwasi Minta, CEO of TEF Labs. "Invitrogen is extremely active in the commercial arena and we are excited about the possibilities of partnering with them with regard to new technologies in the future."

For more information, please visit www.invitrogen.com/probes

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com